Figure 6.

Cell-binding assay showing binding of HCirV VLPs to PLC/PRF/5 cells in study of HCirV in patients with hepatitis. HEV VLPs (bHEV p239) is included as a positive control; SARS-CoV-2 NP protein is included as a negative control. Nuclei are counterstained with DAPI. Cap, capsid; HCirV, human circovirus; HEV, hepatitis E virus; NP, nucleoprotein; VLP, virus-like particle.